866-997-4948(US-Canada Toll Free)

Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Dec 2016

Category :

Pharmaceutical

No. of Pages : 79 Pages

Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pituitary ACTH Hypersecretion Pipeline Review, H2 2016, provides an overview of the Pituitary ACTH Hypersecretion (Metabolic Disorders) pipeline landscape.

Cushing disease is a condition in which the pituitary gland releases too much adrenocorticotropic hormone (ACTH). Symptoms include acne or skin infections, backache, mental changes, such as depression, anxiety, or changes in behavior. Treatment includes surgery and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pituitary ACTH Hypersecretion Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Pituitary ACTH Hypersecretion (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pituitary ACTH Hypersecretion (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Pituitary ACTH Hypersecretion (Cushing Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 1, 2, 5 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Pituitary ACTH Hypersecretion (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pituitary ACTH Hypersecretion (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Pituitary ACTH Hypersecretion (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pituitary ACTH Hypersecretion (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pituitary ACTH Hypersecretion (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pituitary ACTH Hypersecretion (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pituitary ACTH Hypersecretion (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pituitary ACTH Hypersecretion (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Pituitary ACTH Hypersecretion (Cushing Disease) Overview 8
Therapeutics Development 9
Pipeline Products for Pituitary ACTH Hypersecretion (Cushing Disease) - Overview 9
Pipeline Products for Pituitary ACTH Hypersecretion (Cushing Disease) - Comparative Analysis 10
Pituitary ACTH Hypersecretion (Cushing Disease) - Therapeutics under Development by Companies 11
Pituitary ACTH Hypersecretion (Cushing Disease) - Therapeutics under Investigation by Universities/Institutes 12
Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Pituitary ACTH Hypersecretion (Cushing Disease) - Products under Development by Companies 16
Pituitary ACTH Hypersecretion (Cushing Disease) - Products under Investigation by Universities/Institutes 17
Pituitary ACTH Hypersecretion (Cushing Disease) - Companies Involved in Therapeutics Development 18
Amryt Pharma plc 18
Corcept Therapeutics Inc 19
Cyclacel Pharmaceuticals Inc 20
ElexoPharm GmbH 21
Ipsen SA 22
Millendo Therapeutics Inc 23
Novartis AG 24
Orphagen Pharmaceuticals Inc 25
Pfizer Inc 26
Reset Therapeutics Inc 27
Strongbridge Biopharma plc 28
XOMA Corp 29
Pituitary ACTH Hypersecretion (Cushing Disease) - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 34
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
AP-102 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
ATR-101 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
BIM-23B065 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
ketoconazole - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
levoketoconazole - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
mifepristone - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Monoclonal Antibodies to Antagonize Adrenal Corticotropic Hormone Receptor for Cushings Disease - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
MPP-482 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
osilodrostat phosphate - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
pasireotide ER - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
seliciclib - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
Small Molecule to Antagonize Melanocortin Receptor 2 for Cushing's Disease and Congenital Adrenal Hyperplasia - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
Small Molecules to Inhibit CYP11B1 for Cushing's Disease and Subclinical Hypercortisolism - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
Small Molecules to Modulate Cryptochrome for Metabolic and CNS Disorders - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
veldoreotide - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Pituitary ACTH Hypersecretion (Cushing Disease) - Dormant Projects 72
Pituitary ACTH Hypersecretion (Cushing Disease) - Discontinued Products 73
Pituitary ACTH Hypersecretion (Cushing Disease) - Product Development Milestones 74
Featured News & Press Releases 74
Jul 02, 2015: First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing's Disease, a Serious Endocrine Disorder 74
Jan 29, 2015: COR-003 Phase 3 Study Protocol to be Presented at ENDO 2015: The Endocrine Societys 97th Annual Meeting & Expo 74
Oct 03, 2014: Cortendo AB to Present at the 13th Annual BIO Investor Forum in San Francisco October 7, 2014 75
Sep 30, 2014: Cortendo AB to Present at the Epic Biotech Conference in London on October 2, 2014 75
Sep 29, 2014: Cortendo AB to Present at the 14th Annual BIOTECH in Europe Forum in Basel September 30, 2014 75
Aug 12, 2014: First Patient Enrolled into NormoCort Phase 3 SONICS Trial Following a Successful EU Investigator Meeting 75
Jul 09, 2014: CORTENDO Reports Continued Progress On Phase 3 SONICS Trial 76
Jul 30, 2012: Cortendo's NormoCort Receives Orphan Drug Designation From EMA To Treat Cushings Syndrome 76
Mar 15, 2012: Cortendo Receives FDA Orphan Drug Designation For NormoCort In Cushings Syndrome 77
Appendix 78
Methodology 78
Coverage 78
Secondary Research 78
Primary Research 78
Expert Panel Validation 78
Contact Us 78
Disclaimer 79

List of Tables
Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease), H2 2016 9
Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease) - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Number of Products under Investigation by Universities/Institutes, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Development, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Investigation by Universities/Institutes, H2 2016 17
Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Amryt Pharma plc, H2 2016 18
Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Corcept Therapeutics Inc, H2 2016 19
Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016 20
Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by ElexoPharm GmbH, H2 2016 21
Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Ipsen SA, H2 2016 22
Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Millendo Therapeutics Inc, H2 2016 23
Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Novartis AG, H2 2016 24
Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Orphagen Pharmaceuticals Inc, H2 2016 25
Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Pfizer Inc, H2 2016 26
Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Reset Therapeutics Inc, H2 2016 27
Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Strongbridge Biopharma plc, H2 2016 28
Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by XOMA Corp, H2 2016 29
Assessment by Monotherapy Products, H2 2016 30
Number of Products by Stage and Target, H2 2016 32
Number of Products by Stage and Mechanism of Action, H2 2016 35
Number of Products by Stage and Route of Administration, H2 2016 38
Number of Products by Stage and Molecule Type, H2 2016 40
Pituitary ACTH Hypersecretion (Cushing Disease) - Dormant Projects, H2 2016 72
Pituitary ACTH Hypersecretion (Cushing Disease) - Discontinued Products, H2 2016 73

List of Figures
Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease), H2 2016 9
Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease) - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Products, H2 2016 15
Assessment by Monotherapy Products, H2 2016 30
Number of Products by Top 10 Targets, H2 2016 31
Number of Products by Stage and Top 10 Targets, H2 2016 31
Number of Products by Top 10 Mechanism of Actions, H2 2016 34
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 34
Number of Products by Routes of Administration, H2 2016 37
Number of Products by Stage and Routes of Administration, H2 2016 37
Number of Products by Molecule Types, H2 2016 39
Number of Products by Stage and Top 10 Molecule Types, H2 2016 39

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *